ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

APGE Apogee Therapeutics Inc

48,03
1,99 (4,32%)
25 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Apogee Therapeutics Inc APGE NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
1,99 4,32% 48,03 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
46,32 45,6058 49,45 48,03 46,04
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
23.5.202413:30GLOBEApogee Therapeutics to Participate in Upcoming June Investor..
15.5.202422:01GLOBEApogee Announces Dosing of First Patient in Phase 2 Atopic..
13.5.202413:26EDGAR2Form S-8 - Securities to be offered to employees in employee..
13.5.202413:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13.5.202413:05EDGAR2Form 8-K - Current report
13.5.202413:00GLOBEApogee Therapeutics Highlights Pipeline Progress and Reports..
06.5.202414:00GLOBEApogee Therapeutics to Participate at the 2024 Bank of..
25.3.202412:00GLOBEApogee Therapeutics Announces First Participants Dosed in..
12.3.202421:01GLOBEApogee Therapeutics, Inc. Announces Closing of Upsized..
11.3.202411:01EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
08.3.202406:15EDGAR2Form EFFECT - Notice of Effectiveness
08.3.202400:49GLOBEApogee Therapeutics, Inc. Announces Pricing of Upsized $420..
08.3.202400:27EDGAR2Form S-1MEF - Registration adding securities to prior Form..
05.3.202422:23GLOBEApogee Therapeutics, Inc. Announces Proposed..
05.3.202422:05EDGAR2Form S-1 - General form for registration of securities under..
05.3.202414:15EDGAR2Form 8-K - Current report
05.3.202412:15EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
05.3.202412:11EDGAR2Form 8-K - Current report
05.3.202412:10GLOBEApogee Therapeutics Provides Pipeline Progress and Reports..
05.3.202412:00GLOBEApogee Announces Positive Interim Results from Phase 1..
04.3.202422:01GLOBEApogee to Host Conference Call and Webcast to Report Interim..
02.1.202413:30GLOBEApogee Therapeutics to Present at the 42nd Annual J.P...
21.12.202302:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.11.202313:45EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13.11.202313:41EDGAR2Form 8-K - Current report
13.11.202313:30GLOBEApogee Highlights Corporate Progress and Reports Third..
30.10.202313:00GLOBEApogee Therapeutics to Participate in Upcoming November..
27.9.202314:42GLOBEApogee Announces Two Abstracts Accepted for Presentation at..
14.9.202313:30GLOBEApogee Therapeutics to Participate at the 2023 Stifel..
29.8.202314:00PRNUSParagon Therapeutics Recognizes Key Milestones and..
28.8.202313:30GLOBEApogee Highlights Corporate Progress and Reports Second..
21.8.202313:30GLOBEApogee Therapeutics Appoints Mark C. McKenna, Healthcare..
07.8.202313:30GLOBEApogee Announces First Participants Dosed Ahead of Schedule..
02.8.202313:30GLOBEApogee Therapeutics to Participate in Upcoming August..
18.7.202322:01GLOBEApogee Therapeutics, Inc. Announces Closing of Upsized..